Pasteurella hemorrhagic septicemia

Summary

Pasteurella hemorrhagic septicemia (MONDO:0006893) is a disease. A subtype of bacterial infectious disease with sepsis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Pasteurella hemorrhagic septicemia
Mondo ID	MONDO:0006893
EFO	EFO:1001091
MeSH	D006483
SNOMED CT	198462004
GARD	0027768
Is cancer (heuristic)	no

Also known as: bacteremia, haemorrhagic · bacteremia, hemorrhagic · haemorrhagic bacteremia · haemorrhagic Septicaemia · haemorrhagic septicemia · hemorrhagic bacteremia · hemorrhagic Septicaemia · Septicaemia, haemorrhagic · Septicaemia, hemorrhagic · septicemia, haemorrhagic · septicemia, hemorrhagic

Disease family

This is a subtype of bacterial infectious disease with sepsis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial infectious disease with sepsis › Pasteurella hemorrhagic septicemia

Related subtypes (4): gas gangrene, Lemierre syndrome, meningococcemia, neonatal sepsis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.